FCER1G and central nervous system cancer: Moreover, according to analysis of GEO dataset, we also found that the GSE16011 cohort with grade II (n = 24), grade III (n = 85), and grade IV (n = 159) glioma patients (IV versus III: P < 0.001; IV versus II: P < 0.001; III versus III: P = 0.48, Fig. 2d), GSE43289 dataset with 3 grade II, 6 grade III, and 28 grade IV patients (IV versus III: P = 0.3; IV versus II: P = 0.0071; III versus III: P = 0.38, Fig. 2e), and the GSE4412 dataset (26 grade III and 59 grade IV patients, P < 0.0001, Fig. 2f) all exerted higher expression of FCER1G in high grade glioma.